Estudo randomizado | Dose terapêutica de heparina se mostrou superior à dose profilática ou à dose intermediária para tromboprofilaxia em pacientes de alto risco internados com COVID-19.
12 Out, 2021 | 11:22hComentário convidado: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine
Estudos relacionados (alguns resultados conflitantes)
Comentário no Twitter
Thromboprophylaxis w therapeutic-dose LMWH reduced major thromboembolism and death by 32% compared with institutional standard heparin without increased major bleeding among #COVID19 inpatients with elevated D-dimers. The effect wasn't seen in ICU patients https://t.co/Wrgj2Ho5lv
— JAMA Internal Medicine (@JAMAInternalMed) October 7, 2021